AñadirLa Nacióncomo fuente preferida en

Interés Humano

La OMS probará tres nuevos tratamientos contra la covid-19

Los fármacos artesunato, imatinib e infliximab serán puestos a prueba en pacientes de más de 600 hospitales repartidos en 52 países

LAKE CHARLES, LOUISIANA - AUGUST 10: (EDITORIAL USE ONLY) Clinicians work after intubating a COVID-19 patient in the Intensive Care Unit (ICU) at Lake Charles Memorial Hospital on August 10, 2021 in Lake Charles, Louisiana. Hospitalizations for COVID-19 surpassed another record in the state yesterday to 2,720 with Louisiana as one of the nation's epicenters while the spread of the Delta variant continues. More than ninety percent of Louisiana's hospitalized COVID-19 patients are unvaccinated. Lake Charles Memorial currently holds 52 COVID-19 patients, 25 of whom are in the ICU. Mario Tama/Getty Images/AFP == FOR NEWSPAPERS, INTERNET, TELCOS & TELEVISION USE ONLY ==
LAKE CHARLES, LOUISIANA - AUGUST 10: (EDITORIAL USE ONLY) Clinicians work after intubating a COVID-19 patient in the Intensive Care Unit (ICU) at Lake Charles Memorial Hospital on August 10, 2021 in Lake Charles, Louisiana. Hospitalizations for COVID-19 surpassed another record in the state yesterday to 2,720 with Louisiana as one of the nation's epicenters while the spread of the Delta variant continues. More than ninety percent of Louisiana's hospitalized COVID-19 patients are unvaccinated. Lake Charles Memorial currently holds 52 COVID-19 patients, 25 of whom are in the ICU. Mario Tama/Getty Images/AFP == FOR NEWSPAPERS, INTERNET, TELCOS & TELEVISION USE ONLY == MARIO TAMA
AFP
Médicos trabajan después de intubar a un paciente de covid-19 en la Unidad de Cuidados Intensivos (UCI) del Lake Charles Memorial Hospital, el 10 de agosto del 2021, en Louisiana, Estados Unidos. (MARIO TAMA/AFP)

Ginebra. La Organización Mundial de la Salud (OMS) anunció este miércoles el inicio de grandes ensayos internacionales de tres posibles tratamientos contra la covid-19.

Los fármacos artesunato, imatinib e infliximab serán probados en pacientes de más de 600 hospitales repartidos en 52 países.

‌
‌

‌

‌
‌

‌

‌